Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07192432 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
A Phase 1 study of HER2 Expressing Solid Tumors, sponsored by Vironexis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT07192432: Recruiting Phase 1 study of HER2 Expressing Solid Tumors, sponsored by Vironexis Biotherapeutics.
NCT07192432 is a Phase 1 study of HER2 Expressing Solid Tumors that is actively recruiting participants, run by Vironexis Biotherapeutics. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07192432, a Phase 1 study of HER2 Expressing Solid Tumors, is actively recruiting participants, sponsored by Vironexis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Conditions Studied
Interventions
- GENETIC Dose Level 1, VNX-202
- GENETIC Dose Level 2, VNX-202
- GENETIC Dose Level 3, VNX-202
- GENETIC Dose Level 4, VNX-202
Study Locations (3)
California
- Valkyrie Clinical Trials - Los Angeles
Colorado
- SCRI Denver DDU at HealthOne - Denver
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2033-10 |
| Phase | Phase 1 |
What NCT07192432 shows while recruiting
NCT07192432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with HER2 Expressing Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Dose Level 1, VNX-202 is the first listed.
NCT07192432 reports a single indexed study location in California, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07192432 about?
NCT07192432 is a clinical study titled "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)". This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
What is the current status of trial NCT07192432?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-11-18. Estimated completion is 2033-10.
What conditions does trial NCT07192432 study?
This clinical trial studies the following conditions: HER2 Expressing Solid Tumors.
What interventions are being tested in trial NCT07192432?
The interventions under investigation include: Dose Level 1, VNX-202 (GENETIC), Dose Level 2, VNX-202 (GENETIC), Dose Level 3, VNX-202 (GENETIC), Dose Level 4, VNX-202 (GENETIC).
Who is sponsoring clinical trial NCT07192432?
This trial is sponsored by Vironexis Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07192432 being conducted?
This trial has 3 study locations across California, Colorado, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07192432's enrollment target sits among peer trials
27 1464th of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI